

6 Literatur

1. Warshaw, A.L. and C. Fernandez-del Castillo. *Pancreatic carcinoma*. N Engl J Med, 1992. 326(7): p. 455-65.
2. Parker, S.L., T. Tong, S. Bolden, and P.A. Wingo. *Cancer statistics, 1997*. CA Cancer J Clin, 1997. 47(1): p. 5-27.
3. Freelove, R. and A.D. Walling. *Pancreatic cancer: diagnosis and management*. Am Fam Physician, 2006. 73(3): p. 485-92.
4. Yeo, C.J. and J.L. Cameron. *Pancreatic cancer*. Curr Probl Surg, 1999. 36(2): p. 59-152.
5. Landis, S.H., T. Murray, S. Bolden, and P.A. Wingo. *Cancer statistics, 1999*. CA Cancer J Clin, 1999. 49(1): p. 8-31, 1.
6. Yang, G.Y., T.D. Wagner, M. Fuss, and C.R. Thomas, Jr. *Multimodality approaches for pancreatic cancer*. CA Cancer J Clin, 2005. 55(6): p. 352-67.
7. Trede, M., H.D. Saeger, G. Schwall, and B. Rumstadt. *Resection of pancreatic cancer--surgical achievements*. Langenbecks Arch Surg, 1998. 383(2): p. 121-8.
8. Bohmig, M. and S. Rosewicz. *[Pancreatic carcinoma]*. Z Gastroenterol, 2004. 42(3): p. 261-8.
9. Schneider, G., J.T. Siveke, F. Eckel, and R.M. Schmid. *Pancreatic cancer: basic and clinical aspects*. Gastroenterology, 2005. 128(6): p. 1606-25.
10. Lockhart, A.C., M.L. Rothenberg, and J.D. Berlin. *Treatment for pancreatic cancer: current therapy and continued progress*. Gastroenterology, 2005. 128(6): p. 1642-54.

11. Wray, C.J., S.A. Ahmad, J.B. Matthews, and A.M. Lowy. *Surgery for pancreatic cancer: recent controversies and current practice*. Gastroenterology, 2005. 128(6): p. 1626-41.
12. Wanebo, H.J. and M.P. Vezeridis. *Pancreatic carcinoma in perspective. A continuing challenge*. Cancer, 1996. 78(3 Suppl): p. 580-91.
13. van Heek, N.T., K.F. Kuhlmann, R.J. Scholten, S.M. de Castro, O.R. Busch, T.M. van Gulik, H. Obertop, and D.J. Gouma. *Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands*. Ann Surg, 2005. 242(6): p. 781-8, discussion 788-90.
14. Glimelius, B. *Chemotherapy in the treatment of cancer of the pancreas*. J Hepatobiliary Pancreat Surg, 1998. 5(3): p. 235-41.
15. Regine, W.F., W.J. John, and M. Mohiuddin. *Adjuvant therapy for pancreatic cancer: current status*. Front Biosci, 1998. 3: p. E186-92.
16. Andren-Sandberg, A., P.L. Backman, and R. Andersson. *Results of adjuvant therapy in resected pancreatic cancer*. Int J Pancreatol, 1997. 21(1): p. 31-8.
17. Klinkenbijn, J.H., J. Jeekel, T. Sahmoud, R. van Pel, M.L. Couvreur, C.H. Veenhof, J.P. Arnaud, D.G. Gonzalez, L.T. de Wit, A. Hennisman, and J. Wils. *Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group*. Ann Surg, 1999. 230(6): p. 776-82; discussion 782-4.
18. Chong, G. and D. Cunningham. *Gastrointestinal cancer: recent developments in medical oncology*. Eur J Surg Oncol, 2005. 31(5): p. 453-60.

19. Wey, J.S., O. Stoeltzing, and L.M. Ellis. *Vascular endothelial growth factor receptors: expression and function in solid tumors*. Clin Adv Hematol Oncol, 2004. 2(1): p. 37-45.
20. Hotz, H.G., O.J. Hines, T. Foitzik, and H.A. Reber. *Animal models of exocrine pancreatic cancer*. Int J Colorectal Dis, 2000. 15(3): p. 136-43.
21. Dore, J.F., M. Bailly, and S. Bertrand. *Metastases of human tumors in experimental animals*. Anticancer Res, 1987. 7(5B): p. 997-1003.
22. Kerbel, R.S. *Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved*. Cancer Biol Ther, 2003. 2(4 Suppl 1): p. S134-9.
23. Fogh, J., T. Orfeo, J. Tiso, F.E. Sharkey, J.M. Fogh, and W.P. Daniels. *Twenty-three new human tumor lines established in nude mice*. Exp Cell Biol, 1980. 48(3): p. 229-39.
24. Fidler, I.J. *Critical factors in the biology of human cancer metastasis*. Am Surg, 1995. 61(12): p. 1065-6.
25. Sordat, B.C., Ueyaman, Y., Fogh, J. *Metastasis of tumor xenografts in the nude mouse.*, in *The nude mouse in experimental and clinical research*, J. Fogh, Giovanella BC, Editor. 1982, Academic Press: New York. p. 95-143.
26. Fidler, I.J. *The biology of cancer metastasis or, 'you cannot fix it if you do not know how it works'*. Bioessays, 1991. 13(10): p. 551-4.
27. Hoffman, R.M. *Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models?* J Cell Biochem, 1994. 56(1): p. 1-3.
28. Fidler, I.J. *Modulation of the organ microenvironment for treatment of cancer metastasis*. J Natl Cancer Inst, 1995. 87(21): p. 1588-92.

29. Kubota, T. *Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation*. J Cell Biochem, 1994. 56(1): p. 4-8.
30. Mohammad, R.M., A. Al-Katib, G.R. Pettit, V.K. Vaitkevicius, U. Joshi, V. Adsay, A.P. Majumdar, and F.H. Sarkar. *An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies*. Clin Cancer Res, 1998. 4(4): p. 887-94.
31. Marincola, F.M., L.F. Da Pozzo, B.J. Drucker, and W.D. Holder, Jr. *Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model*. Surgery, 1990. 108(5): p. 919-29.
32. Tan, M.H. and T.M. Chu. *Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice*. Tumour Biol, 1985. 6(1): p. 89-98.
33. Vezeridis, M.P., C.M. Doremus, L.M. Tibbetts, G. Tzanakakis, and B.T. Jackson. *Invasion and metastasis following orthotopic transplantation of human pancreatic cancer in the nude mouse*. J Surg Oncol, 1989. 40(4): p. 261-5.
34. An, Z., X. Wang, T. Kubota, A.R. Moossa, and R.M. Hoffman. *A clinical nude mouse metastatic model for highly malignant human pancreatic cancer*. Anticancer Res, 1996. 16(2): p. 627-31.
35. Fu, X., F. Guadagni, and R.M. Hoffman. *A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens*. Proc Natl Acad Sci U S A, 1992. 89(12): p. 5645-9.
36. Reyes, G., A. Villanueva, C. Garcia, F.J. Sancho, J. Piulats, F. Lluís, and G. Capella. *Orthotopic xenografts of human pancreatic carcinomas*

- acquire genetic aberrations during dissemination in nude mice. Cancer Res, 1996. 56(24): p. 5713-9.*
37. Lack, E.E. *Primary tumors of the exocrine pancreas. Classification, overview, and recent contributions by immunohistochemistry and electron microscopy. Am J Surg Pathol, 1989. 13 Suppl 1: p. 66-88.*
 38. Kloppel, G. and B. Maillet. *Histological typing of pancreatic and periampullary carcinoma. Eur J Surg Oncol, 1991. 17(2): p. 139-52.*
 39. Goldin, A., R.K. Johnson, and J.M. Venditti. *Usefulness and limitations of murine tumor models for the identification of new antitumor agents. Antibiot Chemother, 1980. 28: p. 1-7.*
 40. Schmied, B.M., A.B. Ulrich, H. Matsuzaki, T.H. El-Metwally, X. Ding, M.E. Fernandes, T.E. Adrian, W.G. Chaney, S.K. Batra, and P.M. Pour. *Biologic instability of pancreatic cancer xenografts in the nude mouse. Carcinogenesis, 2000. 21(6): p. 1121-7.*
 41. Hall, P.A. and N.R. Lemoine. *Models of pancreatic cancer. Cancer Surv, 1993. 16: p. 135-55.*
 42. Rao, M.S. *Animal models of exocrine pancreatic carcinogenesis. Cancer Metastasis Rev, 1987. 6(4): p. 665-76.*
 43. Longnecker, D.S., B.D. Roebuck, J.D. Yager, Jr., H.S. Lilja, and B. Siegmund. *Pancreatic carcinoma in azaserine-treated rats: induction, classification and dietary modulation of incidence. Cancer, 1981. 47(6 Suppl): p. 1562-72.*
 44. Longnecker, D.S., O.S. Pettengill, B.H. Davis, B.K. Schaeffer, J. Zurlo, H.L. Hong, and E.T. Kuhlmann. *Characterization of preneoplastic and neoplastic lesions in the rat pancreas. Am J Pathol, 1991. 138(2): p. 333-40.*
 45. Grapin-Botton, A. *Ductal cells of the pancreas. Int J Biochem Cell Biol, 2005. 37(3): p. 504-10.*

46. Longnecker, D.S. and T.J. Curphey. *Adenocarcinoma of the pancreas in azaserine-treated rats*. *Cancer Res*, 1975. 35(8): p. 2249-58.
47. Schaeffer, B.K., J. Zurlo, and D.S. Longnecker. *Activation of c-Ki-ras not detectable in adenomas or adenocarcinomas arising in rat pancreas*. *Mol Carcinog*, 1990. 3(3): p. 165-70.
48. Hall, P.A., N.R. Lemoine, G. Murphy, and R.H. Dowling. *Molecular differences between human and experimental pancreaticobiliary diversion-induced rat pancreatic neoplasia*. *Gut*, 1991. 32(5): p. 533-5.
49. Visser, C.J., A.H. Bruggink, M. Korc, M.S. Kobrin, R.A. de Weger, I. Seifert-Bock, W.T. van Blokland, A. van Garderen-Hoetmer, and R.A. Woutersen. *Overexpression of transforming growth factor-alpha and epidermal growth factor receptor, but not epidermal growth factor, in exocrine pancreatic tumours in hamsters*. *Carcinogenesis*, 1996. 17(4): p. 779-85.
50. Pettengill, O.S., R.A. Faris, R.H. Bell, Jr., E.T. Kuhlmann, and D.S. Longnecker. *Derivation of ductlike cell lines from a transplantable acinar cell carcinoma of the rat pancreas*. *Am J Pathol*, 1993. 143(1): p. 292-303.
51. Folkman, J. *Anti-angiogenesis: new concept for therapy of solid tumors*. *Ann Surg*, 1972. 175(3): p. 409-16.
52. Folkman, J. *Angiogenesis in cancer, vascular, rheumatoid and other disease*. *Nat Med*, 1995. 1(1): p. 27-31.
53. Semenza, G.L. *Angiogenesis in ischemic and neoplastic disorders*. *Annu Rev Med*, 2003. 54: p. 17-28.
54. Folkman, J. *Tumor angiogenesis: therapeutic implications*. *N Engl J Med*, 1971. 285(21): p. 1182-6.

55. Folkman, J., K. Watson, D. Ingber, and D. Hanahan. *Induction of angiogenesis during the transition from hyperplasia to neoplasia*. Nature, 1989. 339(6219): p. 58-61.
56. Neufeld, G., T. Cohen, S. Gengrinovitch, and Z. Poltorak. *Vascular endothelial growth factor (VEGF) and its receptors*. Faseb J, 1999. 13(1): p. 9-22.
57. Masood, R., J. Cai, T. Zheng, D.L. Smith, Y. Naidu, and P.S. Gill. *Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma*. Proc Natl Acad Sci U S A, 1997. 94(3): p. 979-84.
58. Wang, H. and J.A. Keiser. *Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1*. Circ Res, 1998. 83(8): p. 832-40.
59. Ferrara, N. *Vascular endothelial growth factor: basic science and clinical progress*. Endocr Rev, 2004. 25(4): p. 581-611.
60. Bergers, G. and L.E. Benjamin. *Tumorigenesis and the angiogenic switch*. Nat Rev Cancer, 2003. 3(6): p. 401-10.
61. Kim, K.J., B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and N. Ferrara. *Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo*. Nature, 1993. 362(6423): p. 841-4.
62. Graepler, F., M. Gregor, and U.M. Lauer. *[Anti-angiogenic therapy for gastrointestinal tumours]*. Z Gastroenterol, 2005. 43(3): p. 317-29.
63. Brown, J.M. and A.J. Giaccia. *The unique physiology of solid tumors: opportunities (and problems) for cancer therapy*. Cancer Res, 1998. 58(7): p. 1408-16.
64. Benjamin, L.E., D. Golijanin, A. Itin, D. Pode, and E. Keshet. *Selective ablation of immature blood vessels in established human tumors*

- follows vascular endothelial growth factor withdrawal. J Clin Invest, 1999. 103(2): p. 159-65.*
65. Kerbel, R.S. *Tumor angiogenesis: past, present and the near future. Carcinogenesis, 2000. 21(3): p. 505-15.*
66. St Croix, B., C. Rago, V. Velculescu, G. Traverso, K.E. Romans, E. Montgomery, A. Lal, G.J. Riggins, C. Lengauer, B. Vogelstein, and K.W. Kinzler. *Genes expressed in human tumor endothelium. Science, 2000. 289(5482): p. 1197-202.*
67. Cianchi, F., C. Cortesini, P. Bechi, O. Fantappie, L. Messerini, A. Vannacci, I. Sardi, G. Baroni, V. Boddi, R. Mazzanti, and E. Masini. *Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology, 2001. 121(6): p. 1339-47.*
68. Li, X.M., Z.Y. Tang, L.X. Qin, J. Zhou, and H.C. Sun. *Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res, 1999. 18(4): p. 511-7.*
69. Liu, D.H., X.Y. Zhang, D.M. Fan, Y.X. Huang, J.S. Zhang, W.Q. Huang, Y.Q. Zhang, Q.S. Huang, W.Y. Ma, Y.B. Chai, and M. Jin. *Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma. World J Gastroenterol, 2001. 7(4): p. 500-5.*
70. Weidner, N., J.P. Semple, W.R. Welch, and J. Folkman. *Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med, 1991. 324(1): p. 1-8.*
71. Tanigawa, N., H. Amaya, M. Matsumura, C. Lu, A. Kitaoka, K. Matsuyama, and R. Muraoka. *Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res, 1997. 57(6): p. 1043-6.*

72. Abdalla, S.A., F. Behzad, S. Bsharah, S. Kumar, S.K. Amini, S.T. O'Dwyer, and N.Y. Haboubi. *Prognostic relevance of microvessel density in colorectal tumours*. *Oncol Rep*, 1999. 6(4): p. 839-42.
73. Bachtary, B., E. Selzer, T.H. Knocke, R. Potter, and A. Obermair. *Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival*. *Cancer Lett*, 2002. 179(2): p. 197-203.
74. Komuro, H., S. Kaneko, M. Kaneko, and Y. Nakanishi. *Expression of angiogenic factors and tumor progression in human neuroblastoma*. *J Cancer Res Clin Oncol*, 2001. 127(12): p. 739-43.
75. Wu, Y., L. Saldana, R. Chillar, and J.V. Vadgama. *Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment*. *Int J Oncol*, 2002. 20(3): p. 509-16.
76. Poon, R.T., I.O. Ng, C. Lau, L.X. Zhu, W.C. Yu, C.M. Lo, S.T. Fan, and J. Wong. *Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study*. *Ann Surg*, 2001. 233(2): p. 227-35.
77. Shalaby, F., J. Rossant, T.P. Yamaguchi, M. Gertsenstein, X.F. Wu, M.L. Breitman, and A.C. Schuh. *Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice*. *Nature*, 1995. 376(6535): p. 62-6.
78. Nissen, N.N., P.J. Polverini, A.E. Koch, M.V. Volin, R.L. Gamelli, and L.A. DiPietro. *Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing*. *Am J Pathol*, 1998. 152(6): p. 1445-52.
79. Tonnesen, M.G., X. Feng, and R.A. Clark. *Angiogenesis in wound healing*. *J Investig Dermatol Symp Proc*, 2000. 5(1): p. 40-6.

80. Krussel, J.S., E.M. Casan, F. Raga, J. Hirchenhain, Y. Wen, H.Y. Huang, P. Bielfeld, and M.L. Polan. *Expression of mRNA for vascular endothelial growth factor transmembraneous receptors Flt1 and KDR, and the soluble receptor sflt in cycling human endometrium*. Mol Hum Reprod, 1999. 5(5): p. 452-8.
81. Karuri, A.R., A.M. Kumar, and D. Mukhopadhyay. *Differential expression and selective localization of vascular permeability factor/vascular endothelial growth factor in the rat uterus during the estrous cycle*. J Endocrinol, 1998. 159(3): p. 489-99.
82. Boehm, T., J. Folkman, T. Browder, and M.S. O'Reilly. *Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance*. Nature, 1997. 390(6658): p. 404-7.
83. Marme, D. *The impact of anti-angiogenic agents on cancer therapy*. J Cancer Res Clin Oncol, 2003. 129(11): p. 607-20.
84. Salmon, J.S., A.C. Lockhart, and J. Berlin. *Anti-angiogenic treatment of gastrointestinal malignancies*. Cancer Invest, 2005. 23(8): p. 712-26.
85. Dreves, J., I. Hofmann, H. Hugenschmidt, C. Wittig, H. Madjar, M. Muller, J. Wood, G. Martiny-Baron, C. Unger, and D. Marme. *Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model*. Cancer Res, 2000. 60(17): p. 4819-24.
86. Wedge, S.R., D.J. Ogilvie, M. Dukes, J. Kendrew, J.O. Curwen, L.F. Hennequin, A.P. Thomas, E.S. Stokes, B. Curry, G.H. Richmond, and P.F. Wadsworth. *ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy*. Cancer Res, 2000. 60(4): p. 970-5.
87. Brekken, R.A., J.P. Overholser, V.A. Stastny, J. Waltenberger, J.D. Minna, and P.E. Thorpe. *Selective inhibition of vascular endothelial*

- growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res, 2000. 60(18): p. 5117-24.*
88. Vitaliti, A., M. Wittmer, R. Steiner, L. Wyder, D. Neri, and R. Klemenz. *Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res, 2000. 60(16): p. 4311-4.*
89. Kabbinavar, F., H.I. Hurwitz, L. Fehrenbacher, N.J. Meropol, W.F. Novotny, G. Lieberman, S. Griffing, and E. Bergsland. *Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 2003. 21(1): p. 60-5.*
90. Jayson, G.C., J. Zweit, A. Jackson, C. Mulatero, P. Julyan, M. Ranson, L. Broughton, J. Wagstaff, L. Hakansson, G. Groenewegen, J. Bailey, N. Smith, D. Hastings, J. Lawrance, H. Haroon, T. Ward, A.T. McGown, M. Tang, D. Levitt, S. Marreaud, F.F. Lehmann, M. Herold, and H. Zwierzina. *Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst, 2002. 94(19): p. 1484-93.*
91. Konner, J. and J. Dupont. *Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer, 2004. 4 Suppl 2: p. S81-5.*
92. Fiedler, W., R. Mesters, H. Tinnefeld, S. Loges, P. Staib, U. Duhrsen, M. Flasshove, O.G. Ottmann, W. Jung, F. Cavalli, R. Kuse, J. Thomalla, H. Serve, A.M. O'Farrell, M. Jacobs, N.M. Brega, P. Scigalla, D.K. Hossfeld, and W.E. Berdel. *A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 2003. 102(8): p. 2763-7.*

93. Ferrara, N., K.J. Hillan, H.P. Gerber, and W. Novotny. *Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer*. Nat Rev Drug Discov, 2004. 3(5): p. 391-400.
94. Itakura, J., T. Ishiwata, B. Shen, M. Kornmann, and M. Korc. *Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer*. Int J Cancer, 2000. 85(1): p. 27-34.
95. Kuehn, R., P.I. Lelkes, C. Bloechle, A. Niendorf, and J.R. Izbicki. *Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer*. Pancreas, 1999. 18(1): p. 96-103.
96. Ikeda, N., M. Adachi, T. Taki, C. Huang, H. Hashida, A. Takabayashi, M. Sho, Y. Nakajima, H. Kanehiro, M. Hisanaga, H. Nakano, and M. Miyake. *Prognostic significance of angiogenesis in human pancreatic cancer*. Br J Cancer, 1999. 79(9-10): p. 1553-63.
97. Seo, Y., H. Baba, T. Fukuda, M. Takashima, and K. Sugimachi. *High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma*. Cancer, 2000. 88(10): p. 2239-45.
98. Niedergethmann, M., R. Hildenbrand, G. Wolf, C.S. Verbeke, A. Richter, and S. Post. *Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection*. Int J Pancreatol, 2000. 28(1): p. 31-9.
99. Garcea, G., C.P. Neal, C.J. Pattenden, W.P. Steward, and D.P. Berry. *Molecular prognostic markers in pancreatic cancer: a systematic review*. Eur J Cancer, 2005. 41(15): p. 2213-36.
100. Makinen, K., S. Loimas, V.M. Kosma, J. Wahlfors, O.S. Pettengill, D.S. Longnecker, R. Johansson, and E. Alhava. *Azaserine-induced rat*

- pancreas tumor model with transplantable cultured cells.* Pancreas, 1998. 16(2): p. 160-4.
101. La Rocca, R.V., C.A. Stein, and C.E. Myers. *Suramin: prototype of a new generation of antitumor compounds.* Cancer Cells, 1990. 2(4): p. 106-15.
 102. Pesenti, E., F. Sola, N. Mongelli, M. Grandi, and F. Spreafico. *Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity.* Br J Cancer, 1992. 66(2): p. 367-72.
 103. Hosang, M. *Suramin binds to platelet-derived growth factor and inhibits its biological activity.* J Cell Biochem, 1985. 29(3): p. 265-73.
 104. Coffey, R.J., Jr., E.B. Leof, G.D. Shipley, and H.L. Moses. *Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells.* J Cell Physiol, 1987. 132(1): p. 143-8.
 105. Wade, T.P., A. Kasid, C.A. Stein, R.V. LaRocca, E.R. Sargent, L.G. Gomella, C.E. Myers, and W.M. Linehan. *Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture.* J Surg Res, 1992. 53(2): p. 195-8.
 106. Waltenberger, J., U. Mayr, H. Frank, and V. Hombach. *Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.* J Mol Cell Cardiol, 1996. 28(7): p. 1523-9.
 107. Mehta, R.R., J.M. Graves, G.D. Hart, A. Shilkaitis, and T.K. Das Gupta. *Growth and metastasis of human breast carcinomas with Matrigel in athymic mice.* Breast Cancer Res Treat, 1993. 25(1): p. 65-71.
 108. Price, J.E. *Metastasis from human breast cancer cell lines.* Breast Cancer Res Treat, 1996. 39(1): p. 93-102.

109. Takano, S., S. Gately, H. Engelhard, A.M. Tsanaclis, and S. Brem. *Suramin inhibits glioma cell proliferation in vitro and in the brain.* J Neurooncol, 1994. 21(3): p. 189-201.
110. Myers, C., M. Cooper, C. Stein, R. LaRocca, M.M. Walther, G. Weiss, P. Choyke, N. Dawson, S. Steinberg, M.M. Uhrich, and et al. *Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.* J Clin Oncol, 1992. 10(6): p. 881-9.
111. Vogelzang, N.J., T. Karrison, W.M. Stadler, J. Garcia, H. Cohn, J. Kugler, T. Troeger, L. Giannone, R. Arrieta, M.J. Ratain, and E.E. Vokes. *A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.* Cancer, 2004. 100(1): p. 65-71.
112. Gagliardi, A., H. Hadd, and D.C. Collins. *Inhibition of angiogenesis by suramin.* Cancer Res, 1992. 52(18): p. 5073-5.
113. Bocci, G., R. Danesi, U. Benelli, F. Innocenti, A. Di Paolo, S. Fogli, and M. Del Tacca. *Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo.* Cancer Chemother Pharmacol, 1999. 43(3): p. 205-12.
114. Ingber, D., T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, H. Brem, and J. Folkman. *Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.* Nature, 1990. 348(6301): p. 555-7.
115. Castronovo, V. and D. Belotti. *TNP-470 (AGM-1470): mechanisms of action and early clinical development.* Eur J Cancer, 1996. 32A(14): p. 2520-7.
116. Logothetis, C.J., K.K. Wu, L.D. Finn, D. Daliani, W. Figg, H. Ghaddar, and J.U. Gutterman. *Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.* Clin Cancer Res, 2001. 7(5): p. 1198-203.

117. Cattelan, A.M., M. Trevenzoli, and S.M. Aversa. *Recent advances in the treatment of AIDS-related Kaposi's sarcoma*. Am J Clin Dermatol, 2002. 3(7): p. 451-62.
118. Kruger, E.A. and W.D. Figg. *TNP-470: an angiogenesis inhibitor in clinical development for cancer*. Expert Opin Investig Drugs, 2000. 9(6): p. 1383-96.
119. Koong, A.C., V.K. Mehta, Q.T. Le, G.A. Fisher, D.J. Terris, J.M. Brown, A.J. Bastidas, and M. Vierra. *Pancreatic tumors show high levels of hypoxia*. Int J Radiat Oncol Biol Phys, 2000. 48(4): p. 919-22.
120. Yokoi, K. and I.J. Fidler. *Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine*. Clin Cancer Res, 2004. 10(7): p. 2299-306.
121. Arbiser, J.L., M.A. Moses, C.A. Fernandez, N. Ghiso, Y. Cao, N. Klauber, D. Frank, M. Brownlee, E. Flynn, S. Parangi, H.R. Byers, and J. Folkman. *Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways*. Proc Natl Acad Sci U S A, 1997. 94(3): p. 861-6.
122. Petit, A.M., J. Rak, M.C. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R.S. Kerbel. *Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors*. Am J Pathol, 1997. 151(6): p. 1523-30.
123. Niklinska, W., T. Burzykowski, L. Chyczewski, and J. Niklinski. *Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis*. Lung Cancer, 2001. 34 Suppl 2: p. S59-64.
124. Yuan, A., C.J. Yu, K.T. Luh, S.H. Kuo, Y.C. Lee, and P.C. Yang. *Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and*

- neoangiogenesis in non-small-cell lung cancer*. J Clin Oncol, 2002. 20(4): p. 900-10.
125. Itakura, J., T. Ishiwata, H. Friess, H. Fujii, Y. Matsumoto, M.W. Buchler, and M. Korc. *Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression*. Clin Cancer Res, 1997. 3(8): p. 1309-16.
 126. Hotz, H.G., O.J. Hines, R. Masood, B. Hotz, T. Foitzik, H.J. Buhr, P.S. Gill, and H.A. Reber. *VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer*. Surgery, 2005. 137(2): p. 192-9.
 127. Shishido, T., T. Yasoshima, R. Denno, M. Mukaiya, N. Sato, and K. Hirata. *Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin*. Jpn J Cancer Res, 1998. 89(9): p. 963-9.
 128. Wild, R., M. Dhanabal, T.A. Olson, and S. Ramakrishnan. *Inhibition of angiogenesis and tumour growth by VEGF₁₂₁-toxin conjugate: differential effect on proliferating endothelial cells*. Br J Cancer, 2000. 83(8): p. 1077-83.
 129. Arora, N., R. Masood, T. Zheng, J. Cai, D.L. Smith, and P.S. Gill. *Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells*. Cancer Res, 1999. 59(1): p. 183-8.
 130. Ramakrishnan, S., T.A. Olson, V.L. Bautch, and D. Mohanraj. *Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo*. Cancer Res, 1996. 56(6): p. 1324-30.
 131. Backer, M.V. and J.M. Backer. *Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins*. Bioconjug Chem, 2001. 12(6): p. 1066-73.

132. Drazin, R., J. Kandel, and R.J. Collier. *Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule.* J Biol Chem, 1971. 246(5): p. 1504-10.
133. Collier, R.J. and J. Kandel. *Structure and activity of diphtheria toxin. I. Thiol-dependent dissociation of a fraction of toxin into enzymically active and inactive fragments.* J Biol Chem, 1971. 246(5): p. 1496-503.
134. Wilson, B.A. and R.J. Collier. *Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: active-site structure and enzymic mechanism.* Curr Top Microbiol Immunol, 1992. 175: p. 27-41.
135. Foda, H.D. and S. Zucker. *Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis.* Drug Discov Today, 2001. 6(9): p. 478-482.
136. Skrzydlewska, E., M. Sulkowska, M. Koda, and S. Sulkowski. *Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.* World J Gastroenterol, 2005. 11(9): p. 1251-66.
137. Westermarck, J. and V.M. Kahari. *Regulation of matrix metalloproteinase expression in tumor invasion.* Faseb J, 1999. 13(8): p. 781-92.
138. Zervos, E.E., A.E. Shafii, M. Haq, and A.S. Rosemurgy. *Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro.* J Surg Res, 1999. 84(2): p. 162-7.
139. Zervos, E.E., J.G. Norman, W.R. Gower, M.G. Franz, and A.S. Rosemurgy. *Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo.* J Surg Res, 1997. 69(2): p. 367-71.
140. Alves, F., U. Borchers, B. Padge, H. Augustin, K. Nebendahl, G. Kloppel, and L.F. Tietze. *Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined*

- immunodeficient (SCID) mouse model*. *Cancer Lett*, 2001. 165(2): p. 161-70.
141. Yunis, A.A., G.K. Arimura, and D.J. Russin. *Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase*. *Int J Cancer*, 1977. 19(1): p. 128-35.
142. Tan, M.H., T. Shimano, and T.M. Chu. *Differential localization of human pancreas cancer-associated antigen and carcinoembryonic antigen in homologous pancreatic tumoral xenograft*. *J Natl Cancer Inst*, 1981. 67(3): p. 563-9.
143. Metzgar, R.S., M.T. Gaillard, S.J. Levine, F.L. Tuck, E.H. Bossen, and M.J. Borowitz. *Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies*. *Cancer Res*, 1982. 42(2): p. 601-8.
144. Rajasekaran, S.A., J. Gopal, C. Espineda, S. Ryazantsev, E.E. Schneeberger, and A.K. Rajasekaran. *HPAF-II, a cell culture model to study pancreatic epithelial cell structure and function*. *Pancreas*, 2004. 29(3): p. e77-83.
145. Kyriazis, A.P., A.A. Kyriazis, D.G. Scarpelli, J. Fogh, M.S. Rao, and R. Lepera. *Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics*. *Am J Pathol*, 1982. 106(2): p. 250-60.
146. Ikeda, Y., M. Ezaki, I. Hayashi, D. Yasuda, K. Nakayama, and A. Kono. *Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice*. *Jpn J Cancer Res*, 1990. 81(10): p. 987-93.
147. Guan, K.L. and J.E. Dixon. *Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase*. *Anal Biochem*, 1991. 192(2): p. 262-7.

148. Mosmann, T. *Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays*. J Immunol Methods, 1983. 65(1-2): p. 55-63.
149. Weidner, N. *Intratumor microvessel density as a prognostic factor in cancer*. Am J Pathol, 1995. 147(1): p. 9-19.
150. Uzzan, B., P. Nicolas, M. Cucherat, and G.Y. Perret. *Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis*. Cancer Res, 2004. 64(9): p. 2941-55.
151. Meert, A.P., B. Martin, P. Delmotte, T. Berghmans, J.J. Lafitte, C. Mascaux, M. Paesmans, E. Steels, J.M. Verdebout, and J.P. Sculier. *The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis*. Eur Respir J, 2002. 20(4): p. 975-81.
152. Weidner, N. *Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow*. J Pathol, 1998. 184(2): p. 119-22.
153. Weidner, N. and J. Folkman. *Tumoral vascularity as a prognostic factor in cancer*. Important Adv Oncol, 1996: p. 167-90.
154. Mordenti, J., K. Thomsen, V. Licko, H. Chen, Y.G. Meng, and N. Ferrara. *Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans*. Toxicol Pathol, 1999. 27(1): p. 14-21.
155. Pocard, M., H. Tsukui, R.J. Salmon, B. Dutrillaux, and M.F. Poupon. *Efficiency of orthotopic xenograft models for human colon cancers*. In Vivo, 1996. 10(5): p. 463-9.
156. Hotz, H.G., H.A. Reber, B. Hotz, T. Yu, T. Foitzik, H.J. Buhr, G. Cortina, and O.J. Hines. *An orthotopic nude mouse model for*

- evaluating pathophysiology and therapy of pancreatic cancer.*
Pancreas, 2003. 26(4): p. e89-98.
157. Naito, S., A.C. von Eschenbach, and I.J. Fidler. *Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice.* J Natl Cancer Inst, 1987. 78(2): p. 377-85.
158. Jacquet, P., O.A. Stuart, R. Dalton, D. Chang, and P.H. Sugarbaker. *Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites.* J Surg Oncol, 1996. 62(2): p. 128-34.
159. Paik, P.S., T. Misawa, M. Chiang, J. Towson, S. Im, A. Ortega, and R.W. Beart, Jr. *Abdominal incision tumor implantation following pneumoperitoneum laparoscopic procedure vs. standard open incision in a syngeneic rat model.* Dis Colon Rectum, 1998. 41(4): p. 419-22.
160. Reid, S.E., E.F. Scanlon, M.W. Kaufman, and M.S. Murthy. *Role of cytokines and growth factors in promoting the local recurrence of breast cancer.* Br J Surg, 1996. 83(3): p. 313-20.
161. Allegretto, M., H. Selkaly, and J.R. Mackey. *Intraoperative saline and gemcitabine irrigation improves tumour control in human squamous cell carcinoma-contaminated surgical wounds.* J Otolaryngol, 2001. 30(2): p. 121-5.
162. Jacquet, P., A.M. Averbach, and N. Jacquet. *Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer.* Eur J Surg Oncol, 1995. 21(5): p. 568-70.
163. Liu, B. and K.Y. Lu. *Neural invasion in pancreatic carcinoma.* Hepatobiliary Pancreat Dis Int, 2002. 1(3): p. 469-76.
164. Cooperman, A.M. *Pancreatic cancer: the bigger picture.* Surg Clin North Am, 2001. 81(3): p. 557-74.

165. Tsutsumi, S., H. Kuwano, N. Morinaga, T. Shimura, and T. Asao. *Animal model of para-aortic lymph node metastasis*. *Cancer Lett*, 2001. 169(1): p. 77-85.
166. Henry, K.J., Jr., J. Wasicak, A.S. Tasker, J. Cohen, P. Ewing, M. Mitten, J.J. Larsen, D.M. Kalvin, R. Swenson, S.C. Ng, B. Saeed, S. Cherian, H. Sham, and S.H. Rosenberg. *Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity*. *J Med Chem*, 1999. 42(23): p. 4844-52.
167. Pour, P., F.W. Kruger, J. Althoff, A. Cardesa, and U. Mohr. *Cancer of the pancreas induced in the Syrian golden hamster*. *Am J Pathol*, 1974. 76(2): p. 349-58.
168. Pour, P., J. Althoff, F.W. Kruger, and U. Mohr. *A potent pancreatic carcinogen in Syrian hamsters: N-nitrosobis(2-oxopropyl)amine*. *J Natl Cancer Inst*, 1977. 58(5): p. 1449-53.
169. Longnecker, D.S., P. Wiebkin, B.K. Schaeffer, and B.D. Roebuck. *Experimental carcinogenesis in the pancreas*. *Int Rev Exp Pathol*, 1984. 26: p. 177-229.
170. Egami, H., T. Tomioka, M. Tempero, D. Kay, and P.M. Pour. *Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters*. *Am J Pathol*, 1991. 138(3): p. 557-61.
171. Pour, P.M., H. Egami, and Y. Takiyama. *Patterns of growth and metastases of induced pancreatic cancer in relation to the prognosis and its clinical implications*. *Gastroenterology*, 1991. 100(2): p. 529-36.
172. Takiyama, Y., H. Egami, and P.M. Pour. *Expression of human tumor-associated antigens in pancreatic cancer induced in Syrian hamsters*. *Am J Pathol*, 1990. 136(3): p. 707-15.

173. Sirivatanauksorn, V., Y. Sirivatanauksorn, and N.R. Lemoine. *Molecular pattern of ductal pancreatic cancer*. Langenbecks Arch Surg, 1998. 383(2): p. 105-15.
174. Hruban, R.H., A.D. van Mansfeld, G.J. Offerhaus, D.H. van Weering, D.C. Allison, S.N. Goodman, T.W. Kensler, K.K. Bose, J.L. Cameron, and J.L. Bos. *K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization*. Am J Pathol, 1993. 143(2): p. 545-54.
175. Scarpa, A., P. Capelli, K. Mukai, G. Zamboni, T. Oda, C. Iacono, and S. Hirohashi. *Pancreatic adenocarcinomas frequently show p53 gene mutations*. Am J Pathol, 1993. 142(5): p. 1534-43.
176. Chang, K.W., S. Laconi, K.A. Mangold, S. Hubchak, and D.G. Scarpelli. *Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas*. Cancer Res, 1995. 55(12): p. 2560-8.
177. Erill, N., M. Cuatrecasas, F.J. Sancho, A. Farre, P.M. Pour, F. Lluís, and G. Capella. *K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines*. Am J Pathol, 1996. 149(4): p. 1333-9.
178. Perugini, R.A., T.P. McDade, F.J. Vittimberga, Jr., and M.P. Callery. *The molecular and cellular biology of pancreatic cancer*. Crit Rev Eukaryot Gene Expr, 1998. 8(3-4): p. 377-93.
179. Hotz, H.G., H.A. Reber, B. Hotz, T. Foitzik, H.J. Buhr, G. Cortina, and O.J. Hines. *An improved clinical model of orthotopic pancreatic cancer in immunocompetent Lewis rats*. Pancreas, 2001. 22(2): p. 113-21.
180. Sweeney, T.M., M.C. Kibbey, M. Zain, R. Fridman, and H.K. Kleinman. *Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases*. Cancer Metastasis Rev, 1991. 10(3): p. 245-54.

181. Kleinman, H.K. and G.R. Martin. *Matrigel: basement membrane matrix with biological activity*. Semin Cancer Biol, 2005. 15(5): p. 378-86.
182. Hawking, F. *Suramin: with special reference to onchocerciasis*. Adv Pharmacol Chemother, 1978. 15: p. 289-322.
183. Qiao, L., J.G. Pizzolo, and M.R. Melamed. *Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells*. Biochem Biophys Res Commun, 1994. 201(2): p. 581-8.
184. Choe, G., W.H. Kim, J.G. Park, and Y.I. Kim. *Effect of suramin on differentiation of human stomach cancer cell lines*. J Korean Med Sci, 1997. 12(5): p. 433-42.
185. Shin, R., Y. Naomoto, Y. Kamikawa, N. Tanaka, and K. Orita. *Effect of suramin on human esophageal cancer cells in vitro and in vivo*. Scand J Gastroenterol, 1997. 32(8): p. 824-8.
186. Fujiuchi, S., Y. Ohsaki, and K. Kikuchi. *Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor*. Oncology, 1997. 54(2): p. 134-40.
187. Walz, T.M., A. Abdiu, S. Wingren, S. Smeds, S.E. Larsson, and A. Wasteson. *Suramin inhibits growth of human osteosarcoma xenografts in nude mice*. Cancer Res, 1991. 51(13): p. 3585-9.
188. Veikkola, T., M. Karkkainen, L. Claesson-Welsh, and K. Alitalo. *Regulation of angiogenesis via vascular endothelial growth factor receptors*. Cancer Res, 2000. 60(2): p. 203-12.
189. Dvorak, H.F., J.A. Nagy, D. Feng, L.F. Brown, and A.M. Dvorak. *Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis*. Curr Top Microbiol Immunol, 1999. 237: p. 97-132.

190. Nagy, J.A., E.M. Masse, K.T. Herzberg, M.S. Meyers, K.T. Yeo, T.K. Yeo, T.M. Sioussat, and H.F. Dvorak. *Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation*. Cancer Res, 1995. 55(2): p. 360-8.
191. Garcia-Schurmann, J.M., H. Schulze, G. Haupt, J. Pastor, B. Allolio, and T. Senge. *Suramin treatment in hormone- and chemotherapy-refractory prostate cancer*. Urology, 1999. 53(3): p. 535-41.
192. Marchetti, D., J. Reiland, B. Erwin, and M. Roy. *Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues*. Int J Cancer, 2003. 104(2): p. 167-74.
193. Dhar, S., J. Gullbo, K. Csoka, E. Eriksson, K. Nilsson, P. Nickel, R. Larsson, and P. Nygren. *Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients*. Eur J Cancer, 2000. 36(6): p. 803-9.
194. Meyers, M.O., A.R. Gagliardi, G.J. Flattmann, J.L. Su, Y.Z. Wang, and E.A. Woltering. *Suramin analogs inhibit human angiogenesis in vitro*. J Surg Res, 2000. 91(2): p. 130-4.
195. Bhargava, P., J.L. Marshall, N. Rizvi, W. Dahut, J. Yoe, M. Figuera, K. Phipps, V.S. Ong, A. Kato, and M.J. Hawkins. *A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer*. Clin Cancer Res, 1999. 5(8): p. 1989-95.
196. Kudelka, A.P., T. Levy, C.F. Verschraegen, C.L. Edwards, S. Piamsomboon, W. Termrungruanglert, R.S. Freedman, A.L. Kaplan, D.G. Kieback, C.A. Meyers, K.A. Jaeckle, E. Loyer, M. Steger, R. Mante, G. Mavligit, A. Killian, R.A. Tang, J.U. Gutterman, and J.J. Kavanagh. *A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix*. Clin Cancer Res, 1997. 3(9): p. 1501-5.

197. Hori, A., S. Ikeyama, and K. Sudo. *Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells*. *Biochem Biophys Res Commun*, 1994. 204(3): p. 1067-73.
198. Budson, A.E., L. Ko, C. Brasel, and J. Bischoff. *The angiogenesis inhibitor AGM-1470 selectively increases E-selectin*. *Biochem Biophys Res Commun*, 1996. 225(1): p. 141-5.
199. Emoto, M., M. Ishiguro, H. Iwasaki, M. Kikuchi, and T. Kawarabayashi. *TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro*. *Anticancer Res*, 2000. 20(1C): p. 601-4.
200. Hotz, H.G., H.A. Reber, B. Hotz, P.C. Sanghavi, T. Yu, T. Foitzik, H.J. Buhr, and O.J. Hines. *Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth*. *J Gastrointest Surg*, 2001. 5(2): p. 131-8.
201. Kumeda, S.I., A. Deguchi, M. Toi, S. Omura, and K. Umezawa. *Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells*. *Anticancer Res*, 1999. 19(5B): p. 3961-8.
202. Kawarada, Y., H. Ishikura, T. Kishimoto, K. Saito, T. Takahashi, H. Kato, and T. Yoshiki. *Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo*. *Pancreas*, 1997. 15(3): p. 251-7.
203. Hotz, H.G., Hines, O. J., Reber, H. A., Yu, T., Buechler, P., Reber, H. A. *Anti-angiogenic therapy for pancreatic cancer: the effect of a neutralizing anti-VEGF antibody in vitro and in vivo*. *Pancreas*, 1999. 19: p. 424.
204. Prewett, M., J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, P. Bohlen, and D.J.

- Hicklin. *Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors*. *Cancer Res*, 1999. 59(20): p. 5209-18.
205. Hicklin, D.J. and L.M. Ellis. *Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis*. *J Clin Oncol*, 2005. 23(5): p. 1011-27.
206. Li, M., H. Yang, H. Chai, W.E. Fisher, X. Wang, F.C. Brunnicardi, Q. Yao, and C. Chen. *Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors*. *Cancer*, 2004. 101(10): p. 2341-50.
207. Hotz, H.G., Hines, O. J., Reber, H. A., Foitzik, T., Buhr, H. J. *Anti-angiogene Therapie mit einem neutralisierenden Anti-VEGF Antikörper reduziert TumorgroÙe und Metastasierung in einem orthotopen Pankreas-Karzinommodell.*, in *Chirurgisches Forum 2000 für experimentelle und klinische Forschung.*, A. Encke, Editor. 2000, Springer-Verlag: Heidelberg. p. 85-88.
208. Liu, N., T. Furukawa, M. Kobari, and M.S. Tsao. *Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma*. *Am J Pathol*, 1998. 153(1): p. 263-9.
209. Liu, C.D., L. Tilch, D. Kwan, and D.W. McFadden. *Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer*. *J Surg Res*, 2002. 102(1): p. 31-4.
210. de Vries, C., J.A. Escobedo, H. Ueno, K. Houck, N. Ferrara, and L.T. Williams. *The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor*. *Science*, 1992. 255(5047): p. 989-91.
211. von Marschall, Z., T. Cramer, M. Hocker, R. Burde, T. Plath, M. Schirner, R. Heidenreich, G. Breier, E.O. Riecken, B. Wiedenmann,

- and S. Rosewicz. *De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop*. *Gastroenterology*, 2000. 119(5): p. 1358-72.
212. Hotz, H.G., P.S. Gill, R. Masood, B. Hotz, H.J. Buhr, T. Foitzik, O.J. Hines, and H.A. Reber. *Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer*. *J Gastrointest Surg*, 2002. 6(2): p. 159-66; discussion 166.
213. Olson, T.A., D. Mohanraj, S. Roy, and S. Ramakrishnan. *Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate*. *Int J Cancer*, 1997. 73(6): p. 865-70.
214. Baker, C.H., C.C. Solorzano, and I.J. Fidler. *Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer*. *Cancer Res*, 2002. 62(7): p. 1996-2003.
215. Bockhorn, M., Y. Tsuzuki, L. Xu, A. Frilling, C.E. Broelsch, and D. Fukumura. *Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts*. *Clin Cancer Res*, 2003. 9(11): p. 4221-6.
216. Bramhall, S.R., A. Rosemurgy, P.D. Brown, C. Bowry, and J.A. Buckels. *Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial*. *J Clin Oncol*, 2001. 19(15): p. 3447-55.
217. Hotz, H.G., O.J. Hines, B. Hotz, T. Foitzik, H.J. Buhr, and H.A. Reber. *Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer*. *J Gastrointest Surg*, 2003. 7(2): p. 220-7; discussion 227-8.

218. Presta, L.G., H. Chen, S.J. O'Connor, V. Chisholm, Y.G. Meng, L. Krummen, M. Winkler, and N. Ferrara. *Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders*. *Cancer Res*, 1997. 57(20): p. 4593-9.
219. Borgstrom, P., M.A. Bourdon, K.J. Hillan, P. Sriramarao, and N. Ferrara. *Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo*. *Prostate*, 1998. 35(1): p. 1-10.
220. Botos, I., L. Scapozza, D. Zhang, L.A. Liotta, and E.F. Meyer. *Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding*. *Proc Natl Acad Sci U S A*, 1996. 93(7): p. 2749-54.
221. Bramhall, S.R. *The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application*. *Int J Pancreatol*, 1997. 21(1): p. 1-12.
222. Giavazzi, R. and G. Taraboletti. *Preclinical development of metalloproteinase inhibitors in cancer therapy*. *Crit Rev Oncol Hematol*, 2001. 37(1): p. 53-60.
223. Jones, L., P. Ghaneh, M. Humphreys, and J.P. Neoptolemos. *The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer*. *Ann N Y Acad Sci*, 1999. 880: p. 288-307.
224. Pepper, M.S. *Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis*. *Arterioscler Thromb Vasc Biol*, 2001. 21(7): p. 1104-17.
225. Raza, S.L. and L.A. Cornelius. *Matrix metalloproteinases: pro- and anti-angiogenic activities*. *J Investig Dermatol Symp Proc*, 2000. 5(1): p. 47-54.

226. Patterson, B.C. and Q.A. Sang. *Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)*. J Biol Chem, 1997. 272(46): p. 28823-5.
227. Jimenez, R.E., W. Hartwig, B.A. Antoniu, C.C. Compton, A.L. Warshaw, and C. Fernandez-Del Castillo. *Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control*. Ann Surg, 2000. 231(5): p. 644-54.
228. Bergers, G., R. Brekken, G. McMahon, T.H. Vu, T. Itoh, K. Tamaki, K. Tanzawa, P. Thorpe, S. Itohara, Z. Werb, and D. Hanahan. *Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis*. Nat Cell Biol, 2000. 2(10): p. 737-44.
229. Haq, M., A. Shafii, E.E. Zervos, and A.S. Rosemurgy. *Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer*. Cancer Res, 2000. 60(12): p. 3207-11.
230. Gasparini, G., R. Longo, M. Fanelli, and B.A. Teicher. *Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions*. J Clin Oncol, 2005. 23(6): p. 1295-311.
231. Kerbel, R.S. and B.A. Kamen. *The anti-angiogenic basis of metronomic chemotherapy*. Nat Rev Cancer, 2004. 4(6): p. 423-36.
232. Gille, J., K. Spieth, and R. Kaufmann. *Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer*. J Dtsch Dermatol Ges, 2005. 3(1): p. 26-32.
233. Song, S., B. Yu, Y. Wei, M.G. Wientjes, and J.L. Au. *Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors*. Clin Cancer Res, 2004. 10(18 Pt 1): p. 6058-65.

234. Backer, M.V., V.G. Budker, and J.M. Backer. *Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2*. J Control Release, 2001. 74(1-3): p. 349-55.
235. Bhargava S, H.B., Buhr HJ, Hotz HG. *Etablierung eines Resektionsmodells des duktaalen Pankreaskarzinoms in der Nacktmaus zur Etablierung neuer adjuvanter Therapien.*, in *Chirurgisches Forum 2006 für experimentelle und klinische Forschung*, J.K. Saeger HD, Bauer H, Editor. 2006, Springer Verlag: Heidelberg. p. 141-142.
236. Hotz, H.G., Bhargava, S., Hotz, B., Buhr, H. J. *An improved rat model of pancreatic cancer mimics the adjuvant situation after surgical resection and reflects aggressive postoperative tumor recurrence*. Langenbecks Arch Surg, 2004. 389: p. 435.